

# Wound Closure Hemostats - Medical Devices Pipeline Assessment, 2017

<https://marketpublishers.com/r/W7DAA679F19EN.html>

Date: October 2017

Pages: 235

Price: US\$ 4,000.00 (Single User License)

ID: W7DAA679F19EN

## Abstracts

Wound Closure Hemostats - Medical Devices Pipeline Assessment, 2017

### SUMMARY

GlobalData's Medical Devices sector report, "Wound Closure Hemostats - Medical Devices Pipeline Assessment, 2017" provides an overview of Wound Closure Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Wound Closure Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

**Note:** Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

### SCOPE

Extensive coverage of the Wound Closure Hemostats under development

The report reviews details of major pipeline products which includes, product

description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Wound Closure Hemostats and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment/industry

## **REASONS TO BUY**

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Wound Closure Hemostats under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date

## Contents

### **1 TABLE OF CONTENTS**

- 1.1 List of Tables
- 1.2 List of Figures

### **2 INTRODUCTION**

- 2.1 Wound Closure Hemostats Overview

### **3 PRODUCTS UNDER DEVELOPMENT**

- 3.1 Wound Closure Hemostats - Pipeline Products by Stage of Development
- 3.2 Wound Closure Hemostats - Pipeline Products by Segment
- 3.3 Wound Closure Hemostats - Pipeline Products by Territory
- 3.4 Wound Closure Hemostats - Pipeline Products by Regulatory Path
- 3.5 Wound Closure Hemostats - Pipeline Products by Estimated Approval Date
- 3.6 Wound Closure Hemostats - Ongoing Clinical Trials

### **4 WOUND CLOSURE HEMOSTATS - PIPELINE PRODUCTS UNDER DEVELOPMENT BY COMPANIES**

- 4.1 Wound Closure Hemostats Companies - Pipeline Products by Stage of Development
- 4.2 Wound Closure Hemostats - Pipeline Products by Stage of Development

### **5 WOUND CLOSURE HEMOSTATS COMPANIES AND PRODUCT OVERVIEW**

- 5.1 3-D Matrix Ltd Company Overview
  - 5.1.1 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.2 Anika Therapeutics Inc Company Overview
  - 5.2.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.3 Arch Therapeutics Inc Company Overview
  - 5.3.1 Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.4 Argon Medical Devices Inc Company Overview
  - 5.4.1 Argon Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.5 Baxter International Inc Company Overview
  - 5.5.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview

- 5.6 Beth Israel Deaconess Medical Center Inc Company Overview
  - 5.6.1 Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.7 Biomedica Management Corp Company Overview
  - 5.7.1 Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.8 Biom'Up SAS Company Overview
  - 5.8.1 Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview
- 5.9 C. R. Bard Inc Company Overview
  - 5.9.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.10 Cellphire Inc Company Overview
  - 5.10.1 Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.11 Ceramicos Para Aplicacoes Medicas Lda Company Overview
  - 5.11.1 Ceramicos Para Aplicacoes Medicas Lda Pipeline Products & Ongoing Clinical Trials Overview
- 5.12 Columbia University Company Overview
  - 5.12.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
- 5.13 Covalent Medical, Inc. (Inactive) Company Overview
  - 5.13.1 Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
- 5.14 Covalon Technologies Ltd Company Overview
  - 5.14.1 Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.15 Cresilon Inc Company Overview
  - 5.15.1 Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.16 CryoLife Inc Company Overview
  - 5.16.1 CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.17 Endomedix Incorporated Company Overview
  - 5.17.1 Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview
- 5.18 Entegriion Inc Company Overview
  - 5.18.1 Entegriion Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.19 Ethicon US LLC Company Overview
  - 5.19.1 Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.20 Gamma Therapeutics Inc Company Overview
  - 5.20.1 Gamma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.21 gel-e Inc Company Overview
  - 5.21.1 gel-e Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.22 Haemostatix Ltd Company Overview
  - 5.22.1 Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.23 Hemostasis LLC Company Overview

- 5.23.1 Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.24 KeraNetics, LLC Company Overview
  - 5.24.1 KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.25 LifeBond Ltd Company Overview
  - 5.25.1 LifeBond Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.26 Resorba GmbH Company Overview
  - 5.26.1 Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview
- 5.27 Rice University Company Overview
  - 5.27.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview
- 5.28 Samyang Biopharmaceuticals Corp Company Overview
  - 5.28.1 Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.29 Sanofi Company Overview
  - 5.29.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview
- 5.30 Sea Run Holdings Inc Company Overview
  - 5.30.1 Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.31 St Teresa Medical Inc Company Overview
  - 5.31.1 St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.32 The Medicines Company Company Overview
  - 5.32.1 The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview
- 5.33 Therus Corporation Company Overview
  - 5.33.1 Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview
- 5.34 Thrombotargets Corp Company Overview
  - 5.34.1 Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.35 United Health Products, Inc. Company Overview
  - 5.35.1 United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview
- 5.36 University of Grenoble Alpes Company Overview
  - 5.36.1 University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview
- 5.37 Virginia Commonwealth University Company Overview
  - 5.37.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
- 5.38 Wound Management Technologies Inc Company Overview
  - 5.38.1 Wound Management Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.39 Xcede Technologies Inc Company Overview
  - 5.39.1 Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview

## 6 WOUND CLOSURE HEMOSTATS - RECENT DEVELOPMENTS

- 6.1 Sep 13, 2017: Advanced Medical Solutions: Interim Results for the six months ended 30 June 2017
- 6.2 Sep 13, 2017: gel-e Expands Core Team with Regulatory, Manufacturing and Financial Talent
- 6.3 Sep 12, 2017: Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5 for Subchronic Systemic Toxicity
- 6.4 Sep 07, 2017: St. Teresa Medical Announces First Commercial Use of SURGICLOT in Auckland, New Zealand
- 6.5 Aug 28, 2017: Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
- 6.6 Aug 22, 2017: United Health Products Reports Second Quarter 2017 Results
- 6.7 Aug 22, 2017: Medtronic Reports First Quarter Financial Results
- 6.8 Aug 21, 2017: Covalon Releases Third Quarter Financial Results
- 6.9 Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results
- 6.10 Aug 09, 2017: Novadaq Receives Court Approval for Arrangement With Stryker
- 6.11 Aug 02, 2017: United Health Products Reports Profitable First Quarter ended March 31, 2017
- 6.12 Aug 02, 2017: Stryker announces election of new Director, Mary K. Brainerd
- 6.13 Jul 31, 2017: Advanced Medical Solutions Group Reports H1 2016 Results
- 6.14 Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER
- 6.15 Jul 31, 2017: Dr. Joachim Schulz joins the Management Board of B. Braun Melsungen
- 6.16 Jul 28, 2017: Indonesian Minister of Health Launches New German Pharmaceutical Factory in Karawang
- 6.17 Jul 27, 2017: Stryker reports second quarter 2017 results
- 6.18 Jul 27, 2017: Anika Announces Appointment of Joseph Darling as President
- 6.19 Jul 26, 2017: Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020
- 6.20 Jul 26, 2017: Merit Medical Reports Record Revenue and Non-GAAP Net Income for Second Quarter 2017, Raises 2017 Guidance and Gives Preliminary 2018-2019 Guidance
- 6.21 Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results
- 6.22 Jul 25, 2017: Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5 Topical Gel
- 6.23 Jul 24, 2017: Ergomed completes Phase IIb study recruitment six months ahead of

schedule for its innovative coagulant PeptoStat

6.24 Jul 24, 2017: CryoLife Reports Second Quarter 2017 Financial Results

6.25 Jul 20, 2017: Wound Management Technologies Announces Q2 2017 Sales Up 15% over Q2 2016 and All Amortized Debt Retired in the Second Quarter

6.26 Jul 18, 2017: Johnson & Johnson Reports 2017 Second-Quarter Results

6.27 Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board

6.28 Jul 12, 2017: Sanofi: Pre-quarterly Results Communication

6.29 Jun 21, 2017: PeptoStat Phase IIb study passes recruitment mid-point ahead of schedule – Top line results brought forward to Q4 2017

6.30 Jun 08, 2017: B. Braun is participating in the third edition of the High-Tech Founders Fund

6.31 Jun 06, 2017: Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

6.32 Jun 06, 2017: Ethicon Announces FDA Approval For SURGICEL Powder Absorbable Hemostat

6.33 Jun 06, 2017: Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

6.34 May 29, 2017: Covalon Releases Second Quarter Financial Results

6.35 May 26, 2017: Merit Medical Announces Appointment of New Director

6.36 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results

6.37 May 17, 2017: Wound Management Issues 2017 10Q and Hires New Strategic Marketing Director

6.38 May 10, 2017: The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures

6.39 May 03, 2017: Anika Reports First Quarter 2017 Financial Results

6.40 May 03, 2017: Covalon to Exhibit at the 2017 European Wound Management Association's Annual Conference

6.41 Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results

6.42 Apr 28, 2017: Advanced Medical Solutions Group Reports 2016 Financial Results

6.43 Apr 27, 2017: Merit Medical Reports Results for First Quarter of 2017

6.44 Apr 27, 2017: Q1 2017 Sales Up 32% Over Q1 2016, for Wound Management Technologies

6.45 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017

6.46 Apr 26, 2017: CryoLife Reports First Quarter 2017 Financial Results

6.47 Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results

6.48 Apr 25, 2017: Stryker reports first quarter 2017 results

- 6.49 Apr 19, 2017: Johnson & Johnson reports Q1 2017 results
- 6.50 Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results
- 6.51 Apr 18, 2017: United Health Products to file late 2016 audited year end
- 6.52 Apr 16, 2017: Establishment of Lohmann & Rauscher Tunisie s.a.r.l.
- 6.53 Apr 12, 2017: Change in the B. Braun Management Board and the Aesculap Management Board
- 6.54 Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia
- 6.55 Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication
- 6.56 Apr 11, 2017: Z-Medica Products Approved For Use In Brazil
- 6.57 Apr 05, 2017: MPP Group Announces Launch Of Dextatic Advanced Wound Care Dressing
- 6.58 Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee
- 6.59 Apr 03, 2017: Baxter Unveils Design Enhancement to FLOSEAL Hemostatic Agent at AORN Meeting
- 6.60 Apr 03, 2017: Baxter Unveils Design Enhancement to TISSEEL Hemostatic Agent at AORN Meeting
- 6.61 Mar 31, 2017: B. Braun continues its sales and earnings growth
- 6.62 Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors
- 6.63 Mar 21, 2017: SeeThruEquity Issues Report on United Health Products
- 6.64 Mar 14, 2017: New Data Indicates Use of Baxter's FLOSEAL in Cardiac and Spinal Surgeries May Be Associated with Lower Hospital Costs
- 6.65 Mar 14, 2017: Advanced Medical Solutions Group: Unaudited preliminary Results for the year ended 31 December 2016
- 6.66 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech
- 6.67 Mar 08, 2017: Wound Management announces appointment of John Siedhoff as Chairman
- 6.68 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia
- 6.69 Mar 02, 2017: Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors
- 6.70 Feb 28, 2017: The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results
- 6.71 Feb 22, 2017: Change in the B. Braun Management Board
- 6.72 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results
- 6.73 Feb 21, 2017: Merit Medical Reports Results for Fourth Quarter and Year Ended



December 31, 2016

6.74 Feb 16, 2017: Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5

6.75 Feb 15, 2017: CryoLife Reports Fourth Quarter and Full Year 2016 Financial Results

6.76 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results

6.77 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011

6.78 Feb 14, 2017: Wound Management Technologies Announces Record Quarterly and Annual Sales Ending December 31, 2016 - Up 147% over Q4 2015, and 63% over 2015

6.79 Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER

6.80 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board

6.81 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors

6.82 Feb 02, 2017: Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics

6.83 Feb 02, 2017: Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics

6.84 Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK

6.85 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results

6.86 Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs

6.87 Jan 30, 2017: Covalon Posts Record First Quarter Financial Results

6.88 Jan 24, 2017: Stryker reports 2016 results and 2017 outlook

6.89 Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results

6.90 Jan 10, 2017: Stryker provides 2016 preliminary net sales results

6.91 Jan 09, 2017: Johnson & Johnson Medical Devices Companies Launch CareAdvantage, a Suite of Holistic, Insights-Driven Capabilities to Help U.S. Health Systems Navigate Value-Based Care

6.92 Jan 03, 2017: Covalon CEO Provides Update on Anticipated Fiscal 2017 Financial Growth

6.93 Dec 08, 2016: Wound Management Technologies Welcomes J. Michael Carmena as its New CFO

6.94 Dec 07, 2016: Biom'up receives CE Mark Approval for HEMOBLAST Bellows, the first active hemostatic powder for management of mild to moderate intra-operative bleedings

6.95 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results

6.96 Nov 18, 2016: Dynasil and Cook Biotech Join Together to Advance Xcede

Technologies Patch through First in Human Trials

6.97 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report

6.98 Nov 03, 2016: ImagenIQ Selected as Imaging CRO for CryoLife's PerClot Intraoperative Hemostasis Pivotal Clinical Trial

6.99 Nov 03, 2016: ImagenIQ Selected as Imaging CRO for CryoLife's PerClot Intraoperative Hemostasis Pivotal Clinical Trial

6.100 Nov 01, 2016: Wound Management Technologies Reports Preliminary Financial Results For Q3 2016 Sales Up 56% over Q3 2015, and 2016 YTD Sales Up 41% over 2015 YTD Sales

6.101 Oct 31, 2016: Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study

6.102 Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results

6.103 Oct 27, 2016: Stryker reports third quarter 2016 results

6.104 Oct 26, 2016: CryoLife Reports Third Quarter 2016 Financial Results

6.105 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results

6.106 Oct 26, 2016: Merit Medical Reports Sales Up 15.3% for the Quarter Ended September 30, 2016

6.107 Oct 26, 2016: The Medicines Company Reports Third-Quarter 2016 Financial Results

6.108 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016

6.109 Oct 25, 2016: James W. Bullock Joins CryoLife Board of Directors

6.110 Oct 24, 2016: Vascular Solutions Reports Third Quarter Results

6.111 Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results

6.112 Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare

## **7 APPENDIX**

7.1 Methodology

7.2 About GlobalData

7.3 Contact Us

7.4 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1: Wound Closure Hemostats - Pipeline Products by Stage of Development

Table 2: Wound Closure Hemostats - Pipeline Products by Segment

Table 3: Wound Closure Hemostats - Pipeline Products by Territory

Table 4: Wound Closure Hemostats - Pipeline Products by Regulatory Path

Table 5: Wound Closure Hemostats - Pipeline Products by Estimated Approval Date

Table 6: Wound Closure Hemostats - Ongoing Clinical Trials

Table 7: Hemostats Companies - Pipeline Products by Stage of Development

Table 8: Hemostats - Pipeline Products by Stage of Development

Table 9: 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview

Table 10: PuraStat Hemostat - Product Status

Table 11: PuraStat Hemostat - Product Description

Table 12: TDM-511 - Product Status

Table 13: TDM-511 - Product Description

Table 14: 3-D Matrix Ltd - Ongoing Clinical Trials Overview

Table 15: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery

Table 16: PuraStat Hemostat - Randomized Controlled Trial Comparing Purastat to Standard Therapy for Haemostasis Control During Endoscopic Submucosal Dissection

Table 17: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 18: Hemostatic Patch - Product Status

Table 19: Hemostatic Patch - Product Description

Table 20: Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 21: AC5 Surgical Hemostatic Device - Product Status

Table 22: AC5 Surgical Hemostatic Device - Product Description

Table 23: AC5 Surgical Hemostatic Device - Internal Use - Product Status

Table 24: AC5 Surgical Hemostatic Device - Internal Use - Product Description

Table 25: Argon Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 26: Hemaseel Thrombin Haemostatic Agent - Product Status

Table 27: Hemaseel Thrombin Haemostatic Agent - Product Description

Table 28: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 29: Hemopatch - Product Status

Table 30: Hemopatch - Product Description

Table 31: Baxter International Inc - Ongoing Clinical Trials Overview

Table 32: Hemopatch - A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (more than 5 Days - PAL)

Table 33: Hemopatch - A Prospective Randomized Trial of Hemopatch Versus No Hemopatch for the Intraoperative Hemostasis During Deceased Donor Renal Transplant

Table 34: Hemopatch - Phase III, Randomized, Unblinded, Controlled Clinical Trial for Evaluating the Effectiveness of the use of the New Hemostatic Patch Hemopatch in Patients undergoing Surgical Liver Resection

Table 35: Hemopatch - Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection with Hemopatch Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial

Table 36: Hemopatch - Prospective, Multicenter, Open-label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak after Lung Resection in High-risk Patients, Applying HEMOPATCH

Table 37: Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 38: Portable Wound Hemostasis System - Product Status

Table 39: Portable Wound Hemostasis System - Product Description

Table 40: Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview

Table 41: ClotFoam - Product Status

Table 42: ClotFoam - Product Description

Table 43: ClotGel - Product Status

Table 44: ClotGel - Product Description

Table 45: ClotSpray - Product Status

Table 46: ClotSpray - Product Description

Table 47: Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview

Table 48: Hemoblast Bellows - Product Status

Table 49: Hemoblast Bellows - Product Description

Table 50: Biom'Up SAS - Ongoing Clinical Trials Overview

Table 51: Hemoblast Bellows - Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of Hemoblast Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries

Table 52: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 53: New Hemostat 1 - Product Status

Table 54: New Hemostat 1 - Product Description

Table 55: New Hemostat 2 - Product Status

- Table 56: New Hemostat 2 - Product Description
- Table 57: Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 58: Thromboderm - Product Status
- Table 59: Thromboderm - Product Description
- Table 60: Thrombosomes - Hemostatic Agent - Product Status
- Table 61: Thrombosomes - Hemostatic Agent - Product Description
- Table 62: Ceramicos Para Aplicacoes Medicas Lda Pipeline Products & Ongoing Clinical Trials Overview
- Table 63: HemoKi - Product Status
- Table 64: HemoKi - Product Description
- Table 65: Columbia University Pipeline Products & Ongoing Clinical Trials Overview
- Table 66: Hemostatic Wound Dressing - Product Status
- Table 67: Hemostatic Wound Dressing - Product Description
- Table 68: Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
- Table 69: CovaSTAT - Product Status
- Table 70: CovaSTAT - Product Description
- Table 71: Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 72: ColActive THP - Product Status
- Table 73: ColActive THP - Product Description
- Table 74: CovaStat BioActive Absorbable Hemostatic Sponge - Product Status
- Table 75: CovaStat BioActive Absorbable Hemostatic Sponge - Product Description
- Table 76: Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 77: TRAUMAGEL - Product Status
- Table 78: TRAUMAGEL - Product Description
- Table 79: VETIGEL - Product Status
- Table 80: VETIGEL - Product Description
- Table 81: CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 82: PerClot - Product Status
- Table 83: PerClot - Product Description
- Table 84: CryoLife Inc - Ongoing Clinical Trials Overview
- Table 85: PerClot - Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot Polysaccharide Hemostatic System
- Table 86: Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview
- Table 87: Surgical Hemostat - Intracranial Surgery - Product Status
- Table 88: Surgical Hemostat - Intracranial Surgery - Product Description

Table 89: Topical Hemostat - Product Status

Table 90: Topical Hemostat - Product Description

Table 91: Entegriion Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 92: Stasix - Product Status

Table 93: Stasix - Product Description

Table 94: Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview

Table 95: Flowable thrombin - Product Status

Table 96: Flowable thrombin - Product Description

Table 97: Next Gen Hemostat Kit - Product Status

Table 98: Next Gen Hemostat Kit - Product Description

Table 99: SURGIFLO - Sterile Field Preparation - Product Status

Table 100: SURGIFLO - Sterile Field Preparation - Product Description

Table 101: Gamma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 102: GammaTF - Product Status

Table 103: GammaTF - Product Description

Table 104: gel-e Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 105: Hemogrip Spray-On Foam - Product Status

Table 106: Hemogrip Spray-On Foam - Product Description

Table 107: Vascular gel-e - External Wounds - Product Status

Table 108: Vascular gel-e - External Wounds - Product Description

Table 109: Vascular gel-e - Internal Surgical Use - Product Status

Table 110: Vascular gel-e - Internal Surgical Use - Product Description

Table 111: Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview

Table 112: HaemoPlax - Product Status

Table 113: HaemoPlax - Product Description

Table 114: PeptoStat - Product Status

Table 115: PeptoStat - Product Description

Table 116: Haemostatix Ltd - Ongoing Clinical Trials Overview

Table 117: PeptoStat - A Controlled, Randomized, Multi-center, Double Blind, Phase II Study to Evaluate Efficacy and Safety of Topical PeptoStat in Intraoperative Surgical Haemostasis

Table 118: Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview

Table 119: ENT Hemostat - Product Status

Table 120: ENT Hemostat - Product Description

Table 121: Hemostatic Gel - Product Status

Table 122: Hemostatic Gel - Product Description

Table 123: KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview

Table 124: Keratin-Based Hemostat - Product Status

Table 125: Keratin-Based Hemostat - Product Description

Table 126: LifeBond Ltd Pipeline Products & Ongoing Clinical Trials Overview

Table 127: Absorbable Hemostats - Product Status

Table 128: Absorbable Hemostats - Product Description

Table 129: LifePatch Heavy - Product Status

Table 130: LifePatch Heavy - Product Description

Table 131: LifePatch Surgery - Product Status

Table 132: LifePatch Surgery - Product Description

Table 133: Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview

Table 134: Antibiotic Hemostat - Product Status

Table 135: Antibiotic Hemostat - Product Description

Table 136: GENTA-COLL Resorb - Product Status

Table 137: GENTA-COLL Resorb - Product Description

Table 138: GENTA-FOIL Resorb - Product Status

Table 139: GENTA-FOIL Resorb - Product Description

Table 140: KOLLAGEN resorb - Product Status

Table 141: KOLLAGEN resorb - Product Description

Table 142: RESORBA CELL Fibrillar - Product Status

Table 143: RESORBA CELL Fibrillar - Product Description

Table 144: RESORBA CELL forte - Product Status

Table 145: RESORBA CELL forte - Product Description

Table 146: RESORBA CELL standard - Product Status

Table 147: RESORBA CELL standard - Product Description

Table 148: Rice University Pipeline Products & Ongoing Clinical Trials Overview

Table 149: KOD Hydrogel Hemostat - Product Status

Table 150: KOD Hydrogel Hemostat - Product Description

Table 151: Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview

Table 152: B6102 - Hemostat - Product Status

Table 153: B6102 - Hemostat - Product Description

Table 154: Sanofi Pipeline Products & Ongoing Clinical Trials Overview

Table 155: LeSeal - Product Status

Table 156: LeSeal - Product Description

Table 157: Lumagel - Product Status

Table 158: Lumagel - Product Description

Table 159: Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview

Table 160: SEA-STAT - Product Status

Table 161: SEA-STAT - Product Description

Table 162: St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview

- Table 163: SURGICLOT - Product Status
- Table 164: SURGICLOT - Product Description
- Table 165: WRAPCLOT - Product Status
- Table 166: WRAPCLOT - Product Description
- Table 167: The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview
- Table 168: Fibropad Patch - Product Status
- Table 169: Fibropad Patch - Product Description
- Table 170: Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview
- Table 171: Therus Acoustic Hemostasis System - Product Status
- Table 172: Therus Acoustic Hemostasis System - Product Description
- Table 173: Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview
- Table 174: Next Generation TT-173 - Product Status
- Table 175: Next Generation TT-173 - Product Description
- Table 176: TT-173 - Product Status
- Table 177: TT-173 - Product Description
- Table 178: United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview
- Table 179: HemoStyp General Surgeries Gauze - Product Status
- Table 180: HemoStyp General Surgeries Gauze - Product Description
- Table 181: HemoStyp Internal And External Procedure Gauze - Product Status
- Table 182: HemoStyp Internal And External Procedure Gauze - Product Description
- Table 183: HemoStyp Trauma Gauze - Product Status
- Table 184: HemoStyp Trauma Gauze - Product Description
- Table 185: University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview
- Table 186: Bleeding Controlling Device - Product Status
- Table 187: Bleeding Controlling Device - Product Description
- Table 188: Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
- Table 189: BioHemostat - Product Status
- Table 190: BioHemostat - Product Description
- Table 191: Wound Management Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 192: HemaQuell - Product Status
- Table 193: HemaQuell - Product Description
- Table 194: Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 195: Xcede - Femoral Artery - Product Status



Table 196: Xcede - Femoral Artery - Product Description  
Table 197: Xcede - Laparoscopic Surgery - Product Status  
Table 198: Xcede - Laparoscopic Surgery - Product Description  
Table 199: Xcede - Vascular Surgery - Product Status  
Table 200: Xcede - Vascular Surgery - Product Description  
Table 201: Xcede Hemostatic Patch - Product Status  
Table 202: Xcede Hemostatic Patch - Product Description  
Table 203: Glossary

## List Of Figures

### LIST OF FIGURES

Figure 1: Wound Closure Hemostats - Pipeline Products by Stage of Development

Figure 2: Wound Closure Hemostats - Pipeline Products by Segment

Figure 3: Wound Closure Hemostats - Pipeline Products by Territory

Figure 4: Wound Closure Hemostats - Pipeline Products by Regulatory Path

Figure 5: Wound Closure Hemostats - Pipeline Products by Estimated Approval Date

Figure 6: Wound Closure Hemostats - Ongoing Clinical Trials

### COMPANIES MENTIONED

3-D Matrix Ltd

Anika Therapeutics Inc

Arch Therapeutics Inc

Argon Medical Devices Inc

Baxter International Inc

Beth Israel Deaconess Medical Center Inc

Biomedica Management Corp

Biom'Up SAS

C. R. Bard Inc

Cellphire Inc

Ceramicos Para Aplicacoes Medicas Lda

Columbia University

Covalent Medical, Inc.

Covalon Technologies Ltd

Cresilon Inc

CryoLife Inc

Endomedix Incorporated

Entegriion Inc

Ethicon US LLC

Gamma Therapeutics Inc

gel-e Inc

Haemostatix Ltd

Hemostasis LLC

KeraNetics, LLC

LifeBond Ltd

Resorba GmbH

Rice University  
Samyang Biopharmaceuticals Corp  
Sanofi  
Sea Run Holdings Inc  
St Teresa Medical Inc  
The Medicines Company  
Therus Corporation  
Thrombotargets Corp  
United Health Products, Inc.  
University of Grenoble Alpes  
Virginia Commonwealth University  
Wound Management Technologies Inc  
Xcede Technologies Inc

## I would like to order

Product name: Wound Closure Hemostats - Medical Devices Pipeline Assessment, 2017

Product link: <https://marketpublishers.com/r/W7DAA679F19EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W7DAA679F19EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970